Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling
© The Author(s). 2017
Received: 22 August 2017
Accepted: 23 October 2017
Published: 2 November 2017
Clinically, breast cancer is generally classified into estrogen receptor-positive (ER+) or estrogen receptor-negative (ER−) subtypes. The phytoestrogen calycosin has been shown to inhibit the proliferation of ER+ cells, which may be mediated by a feedback loop that involves miR-375, RAS dexamethasone-induced 1 (RASD1), and ERα. However, how calycosin acts on ER− breast cancer cells remains unclear.
Here, we show that calycosin inhibited the proliferation of both ER− (MDA-MB-468 and SKBR3) and ER+ breast cancer cells (MCF-7 and T47D) and that these inhibitory effects were associated with the up-regulation of the long non-coding RNA (lncRNA) WDR7-7. For the first time, we demonstrate that the expression of WDR7-7 is reduced in breast cancer cell lines and that the overexpression of WDR7-7 inhibits growth through a mechanism that involves G-protein coupled estrogen receptor 30 (GPR30). Meanwhile, we show that calycosin stimulated the WDR7-7-GPR30 signaling pathway in MCF-7, T47D, MDA-MB-468, and SKBR3 breast cancer cells. In contrast, in MCF10A and GPR30-deficient MDA-MB-231 cells, due to a lack of WDR7-7-GPR30 for activation, calycosin failed to inhibit cell growth. Additionally, in all four GPR30-positive breast cancer lines, calycosin decreased the phosphorylation levels of SRC, EGFR, ERK1/2 and Akt, but the inhibition of WDR7-7 blocked these changes and increased proliferation. In mice bearing MCF-7 or SKBR3 xenografts, tumor growth was inhibited by calycosin, and changes in expression the levels of WDR7-7 and GPR30 in tumor tissues were similar to those in cultured MCF-7 and SKBR3 cells.
These results suggest the possibility that calycosin inhibited the proliferation of breast cancer cells, at least partially, through WDR7-7-GPR30 signaling, which may explain why calycosin can exert inhibitory effects on ER− breast cancer.
Breast cancer is the second leading cause of cancer-related death among women in developed countries and ranks as the most frequent cause of cancer-related death in women in less developed regions of the world. Approximately 231,840 new cases of invasive breast cancer and 40,290 deaths were expected in the US women in 2015 . Notably, the incidence rate of breast cancer in East Asian countries is lower than that in the US and in developed European countries, which may be due to higher amounts of phytoestrogen consumption in the former . Phytoestrogens warrant investigation in breast cancer research because they are structurally similar to estrogen and exert estrogenic effects on breast cancer cells in low-estrogen environments but antiestrogenic effects in high-estrogen environments . Plant-derived phytoestrogens can be divided into four main classes: isoflavones, coumestans, lignans, and stilbenes. Epidemiological studies and animal studies suggest that increased isoflavone intake from soy consumption may be associated with a decreased risk of developing breast cancer [4, 5].
However, in experimental studies using isoflavones for the prevention and treatment of human breast cancer, the data are conflicting [6, 7]. Clinically, breast cancer is generally classified into estrogen receptor-positive (ER+) or estrogen receptor-negative (ER−) subtypes. Isoflavones, such as genistein, daidzein, and formononetin, have been widely demonstrated to suppress the growth of ER+ breast cancer by binding to estrogen receptors [8–10]. The isoflavone calycosin (Molecular Formula: C16H12O5, Molecular Weight: 284.26, Fig. 5h) is a phytoestrogen and the main active component of Radix Astragali. Results from our previous study suggest that calycosin inhibits the proliferation of ER+ breast cancer cells and that miR-375, RAS dexamethasone-induced 1 (RASD1), and ER may be involved in this process [11, 12]. Unexpectedly, we found that calycosin also successfully inhibited the proliferation of ER− breast cancer cells in low-serum medium, although the effects were not as pronounced as ER+ breast cancer cells. These results indicate that in addition to ER-mediated signaling pathways, non-ER-mediated pathways are also involved in the calycosin-mediated regulation of breast cancer proliferation. Given the more aggressive biology of ER− breast cancers, calycosin treatment may result in better clinical outcomes than other phytoestrogens. Therefore, we focused on the antitumor effect of isoflavones against ER− breast cancer, the possible differences between ER+ and ER− breast cancer cells after treatment with calycosin, and the role of non-ER-mediated signaling in these effects.
The understanding of the importance of long ncRNAs (lncRNAs), a new class of non-coding RNAs (ncRNAs), in tumorigenesis is increasing. Recent evidence has suggested that lncRNA-mediated biology has a central role in cancer progression [13–15]. In our preliminary screen of lncRNAs in SKBR3 breast cancer cells, we saw that calycosin increased the expression of several lncRNAs, including WDR7-7, TTC21B-AS1, and CTA-384D8.34. Since WDR7-7 showed the greatest average increase in expression, we chose to examine the role of WDR7-7 in breast cancer carcinogenesis.
The target of WDR7-7, G-protein coupled estrogen receptor 30 (GPR30, formerly known as GPER), was present in both ER+ and ER− breast cancer cells, as confirmed by a luciferase reporter assay. Interestingly, GPR30 is an alternative ER that functions independently of the classical ER pathway and plays a key role in non-estrogen receptor-mediated pathways . Several studies have shown that the inhibition of GPR30 signaling can elicit inhibitory effects on the growth of ER− breast cancer cells, but other studies show the opposite effect [17–20]. The effects of GPR30 on the proliferation of ER− breast cancer cells and the downstream signaling mechanisms of GPR30 urgently require further investigation. Therefore, in this study, we aimed to identify the function of GPR30 in breast cancer and the association between WDR7-7 and GPR30 signaling. In addition, we examined whether the WDR7-7-mediated regulation of the GPR30 pathway might be involved in the inhibitory effect induced by calycosin on breast cancer cells, especially in ER− breast cancer cells.
This study was composed of three parts: in vitro experiments in MCF-7, T47D, SKBR3, MDA-MB-468, MDA-MB-231, and MCF10A cells; in vitro analysis of breast cancer and paracancerous tissues samples; and in vivo experiments in nude mice bearing MCF-7-xenografts and SKBR3-xenografts.
For in vitro experiments, MCF-7, T47D, SKBR3, MDA-MB-468, MDA-MB-231, and MCF10A cells were treated with calycosin (Sigma, St. Louis, MO, USA, purity >98%) at concentrations of 1–32 μM. Then, cell growth was measured using a CCK-8 assay, BrdU assay, and colony formation assay. SKBR3 cells were treated with 16 μM calycosin for 48 h in a microarray screen to identify the lncRNAs that are specially regulated by calycosin. The target gene of WDR7-7, GPR30, was confirmed using luciferase reporter assays and quantitative real-time polymerase chain reaction (qRT-PCR). In the next set of experiments, MCF-7, T47D, SKBR3, MDA-MB-468, MDA-MB-231, and MCF10A cells were treated with calycosin (16 μM); then, the mRNA and proteins expression levels (WDR7-7, GPR30, p-SRC, phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated protein kinase B (p-Akt), and phosphorylated extracellular signal-regulated kinases (p-ERK1/2)) were measured using qRT-PCR and Western blotting. In some experiments, cells were pretreated for 20 h with the pCDNA3.1-WDR7-7 plasmid constructs, pCDNA3.1(+) vector, or WDR7-7 shRNA (100 nM; XuanC Bio, Nanning, Guangxi, China) prior to treatment with calycosin (16 μM).
For patients and specimen experiments, breast cancer and paracancerous tissues were used for immunohistochemical (IHC) staining and Western blotting analysis. Tissues were collected from breast cancer patients who underwent curative resection between 2013 and 2016 at the Department of Breast and Thyroid Surgery, First Affiliated Hospital of Guilin Medical University. None of the patients had received chemotherapy or radiotherapy before surgery. The study protocols were approved by the hospital ethics committee and the study was conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent.
For the in vivo experiments, all procedures were approved by the Animal Research Ethics Committee of Guilin Medical University. MCF-7 or SKBR3 cells were implanted subcutaneously into female nude mice (6–8 weeks old, n = 6 mice per condition). When the tumors reached a volume of 0.2 cm3 (approximately 10 days later), the mice were treated with calycosin (55 mg/kg/day), calycosin and pCDNA3.1-WDR7-7, or calycosin and WDR7-7 shRNA for 20 consecutive days.
Cell culture and counting
MCF-7, T47D, SKBR3, MDA-MB-468, MDA-MB-231, and MCF10A cells were obtained from the Shanghai Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai, China) and cultured in a humidified atmosphere with 5% CO2 at 37 °C. MCF-7, T47D, MDA-MB-468, MDA-MB-231, and SKBR3 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS and 1% penicillin-streptomycin. MCF10A cells were cultured in DMEM-F12 (Invitrogen) containing 5% horse serum (HS, Invitrogen), 0.5 μg/ml hydrocortisone (Sigma), 10 μg/mL insulin (Sigma), 0.02 μg/ml EGF (Pepro Tech, Rocky Hill, NJ, USA), 0.1 μg/mL cholera toxin (Sigma), and penicillin-streptomycin. All cell lines were cultured in low-serum medium (1% FBS or HS) for 24 h prior to the experiments. Cell proliferation was examined using a CCK 8 kit (Sigma) and a BrdU kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer’s instructions. For colony formation assays, the cells were seeded in six-well plates. After incubation for 10, 14, and 18 days, the cell colonies were stained with 0.1% (w/v) crystal violet, photographed and then counted. Colony-forming efficiency (CFE) was calculated by the number of colonies formed divided by the total number of cells plated and is expressed as a percentage.
Microarray of lncRNAs
Total RNA (including small RNAs) was extracted from SKBR3 cells using a miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA amplification and labeling were completed using the Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion, Austin, TX, USA). Labeled cDNA was hybridized to a human lncRNA OneArray Plus Microarray (Phalanx Biotech Group, Hsinchu, Taiwan). After washing the slides, the arrays were scanned by an Agilent scanner (Agilent Technologies, Palo Alto, CA, USA), and data on the differential expression of lncRNAs were generated by Agilent Feature Extraction software (version 126.96.36.199).
Gene function analysis
To identify the functions of lncRNAs, the predicted target genes of differentially expressed lncRNAs were added to the Database for Annotation, Integrated Discovery, and Visualization. A GO analysis was performed to analyze the functions represented in the lncRNA profile (XuanC Bio). Furthermore, the significant pathways of these differentially expressed lncRNAs were determined by the Kyoto Encyclopedia of Genes and Genomes database.
Luciferase reporter assay
Lipofectamine 2000 (Invitrogen) was used to co-transfect MCF-7 and SKBR3 cells with a luciferase reporter plasmid (Promega, Madison, WI, USA) containing the wild-type or mutated 3′ UTR of the GPR30 gene downstream of the Renilla luciferase gene with a plasmid encoding hsa-WDR7-7 (XuanC Bio). After 48 h, luciferase activity was measured using a dual-luciferase assay system (Promega) and normalized to the activity of the Renilla luciferase internal control for transfection efficiency.
Tumor samples and histological examination
Sections of paraffin-embedded breast cancer specimens were subjected to HE and IHC staining. For IHC, the sections were deparaffinized, hydrated, and immersed in 1% hydrogen peroxide in methanol for 30 min to block the endogenous peroxidase activity. The sections were incubated with rabbit anti-GPR30 polyclonal antibody (Abcam, Cambridge, Cambridgeshire, UK, diluted 1:250) overnight at 4 °C. After being washed with PBS, the sections were incubated with biotinylated secondary antibody (diluted 1:100) for 30 min at 37 °C, followed by exposure to horseradish peroxidase-conjugated goat anti-rabbit IgG for 20 min at 37 °C. The immunoreactive signal was visualized by the DAB detection system.
Lipofectamine 2000 (Invitrogen) was used to transfect MCF-7, T47D, SKBR3, MDA-MB-468, MDA-MB-231, and MCF10A cells with hsa-miR-375, pCDNA3.1-WDR7-7, miR-375 siRNA, or WDR7-7 shRNA (XuanC Bio).
Total RNA was extracted using TRIzol reagent and reverse transcribed into cDNA using a Revert Aid First Strand cDNA Synthesis Kit (Fermentas, Hanover, MD, USA). The relative expression levels of miR-375, WDR7-7, and GPR30 were measured by qRT-PCR using specific primers (Additional file 1: Table S1) and the SYBR Green qPCR Master Mix (Fermentas). The data were calculated using ABI 7500 software v2.0.1 (Applied Biosystems, Waltham, MA, USA). The expression levels of GPR30 and WDR7-7 were normalized to β-actin expression, and the expression level of miR-375 was normalized to U6 snRNA.
Proteins were extracted from tissues or cells using RIPA buffer (Beyotime, Nanjing, Jiangsu, China), separated by SDS-PAGE, and transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). The membranes were incubated with primary antibodies (Sigma, diluted 1:500 to 1:1000) against the following proteins: ERα, RASD1, β-actin, GPR30, p-SRC, SRC, p-EGFR, EGFR, p-ERK1/2, ERK1/2, p-Akt, and Akt. The blots were washed three times, incubated with the appropriate secondary antibodies (Beyotime), and then visualized with enhanced chemiluminescence reagents (Beyotime). Band intensities were quantified using Image-Pro Plus 5.02 software (Media Cybernetics, Bethesda, MD, USA). The intensities of the ERα, RASD1, and GPR30 bands were normalized to the intensity of the corresponding β-actin band, and the intensity of phosphorylated proteins was normalized to that of the corresponding unphosphorylated proteins.
Mice were injected subcutaneously with 1 × 107 MCF-7 or SKBR3 cells. When the tumor reached 2 cm in diameter, it was divided into pieces approximately 1 mm × 1 mm × 1 mm. These pieces were implanted into 24 recipient mice. When the tumors reached a size of 0.2 cm3, the mice were treated with calycosin (0, 55 mg/kg), 55 mg/kg calycosin and pCDNA3.1-WDR7-7, or 55 mg/kg calycosin and WDR7-7 shRNA for 20 days. Tumor growth was examined every 4 days and the tumors were harvested after 30 days to determine the expression levels of WDR7-7 and GPR30 using qRT-PCR and Western blotting.
The results are expressed as the means ± standard deviations. Comparisons between multiple groups were made using a one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test. Statistical analyses were conducted with SPSS 19.0 software (IBM, Chicago, IL, USA). Significance was defined as p < 0.05.
Concentration- and cell type-dependent effects of calycosin on cell proliferation
Involvement of the miR-375-ERα feedback loop in calycosin-regulated proliferation in MCF-7 and T47D cells
The expression of WDR7-7 and GPR30 in breast cancer cells and tissues
Involvement of the WDR7-7-GPR30 signaling pathway in the proliferation of breast cancer cells
Previous studies have linked GPR30 expression to the non-receptor tyrosine kinase (Src)-dependent activation of EGFR signaling in a variety of estrogen-responsive cancer cells . Activation of the Src/EGFR pathway plays a role in the promotion of cell transformation, proliferation and survival . Consistent with the increased cell viability in breast cancer cells, pretreatment with WDR7-7 shRNA significantly triggered the up-regulation of GPR30 and the phosphorylation of SRC and EGFR and subsequently increased the phosphorylation levels of ERK1/2 and Akt in all four breast cancer cells (p < 0.05; Fig. 4a-f). In contrast, WDR7-7 overexpression led to the inhibition of the GPR30-mediated phosphorylation of SRC, EGFR, ERK1/2, and Akt, ultimately resulting in reduced cell growth. Together, these findings suggest that SRC, EGFR, ERK1/2, and Akt, which are key regulators of cell proliferation and survival in breast cancer cells, act as downstream effectors of the WDR7-7-GPR30 pathway, especially in ER− cells due to the absence of an ER-mediated pathway.
The effects of calycosin on the WDR7-7-GPR30 signaling pathway
The effects of calycosin on tumor xenografts
ERs are involved in the development and progression of estrogen-related cancers, such as breast cancer, ovarian cancer, and prostate cancer [24–26]. Evidently, some phytoestrogens are structurally similar to estrogen and may elicit inhibitory effects on tumor cell proliferation by binding ERs [27, 28]. Likewise, in this study, we demonstrated that calycosin successfully inhibited the growth of ER+ MCF-7 and T47D breast cancer cells, which was mediated by the inactivation of the miR-375-ERα feedback loop. Interestingly, calycosin also had an inhibitory effect on the viability of ER− MDA-MB-468 and SKBR3 cells but not on the proliferation of ER− MCF10A cells. This indicates that, other than normal human breast epithelial cells, calycosin mediates its effects on breast cancer at least in part through mechanisms that are independent of classical estrogen receptors.
In addition to ERs, studies have shown that GPR30, a G protein-coupled receptor, can also be activated by estrogen and play an important role in cancer development . However, some controversy remains on whether GPR30 inhibits or promotes breast cancer development [30–32]. Here, we validated by IHC and Western blotting that GPR30 expression is up-regulated in breast cancer tissues, implying that activation of the GPR30 signaling pathway may be involved in the proliferation of breast cancer cells. However, less is known about the molecular basis of GPR30 in breast cancer and the possible interactions between phytoestrogens and the GPR30-mediated signaling pathway.
Microarray screening identified 152 lncRNAs in SKBR3 cells that were up-regulated by calycosin. The effect was greatest in the case of WDR7-7. Moreover, the down-regulation of WDR7-7 expression was confirmed in both breast cancer cells lines, including MCF-7, T47D, SKBR3, MDA-MB-468, and MDA-MB-231 cells. We found that the overexpression of WDR7-7 in breast cancer cells decreased proliferation, and that silencing WDR7-7 led to increased cell survival. In this regard, we believe that WDR7-7 may function as a tumor suppressor to inhibit cell growth in breast cancer. Interestingly, our luciferase reporter assays confirmed GPR30 as a target of WDR7-7 in breast cancer cells. We also found that the overexpression of WDR7-7 down-regulated GPR30 and that the shRNA-mediated knock down of WDR7-7 up-regulated GPR30. Therefore, we provide evidence that, in addition to the miR-375-ERα feedback loop in ER+ breast cancer cells, a negative relationship between WDR7-7 and GPR30 exists in both ER+ and ER− breast cancer cells.
In the present study, calycosin was found to down-regulate GPR30 by increasing WDR7-7 expression in all breast cancer cells, and the inhibition of WDR7-7 expression significantly reduced the antiproliferative effects of calycosin. MDA-MB-231 breast cancer cells lack GPR30 expression, so treatment with 16 μM calycosin did not suppress cell growth. Furthermore, the involvement of WDR7-7-GPR30 signaling was observed in vivo. Calycosin decreased tumor weight and volume in both ER+ MCF-7 and ER− SKBR3 xenografts, and in cancer tissues, calycosin increased the expression of WDR7-7 but decreased the expression of GPR30. Similarly, these effects were attenuated after pretreatment with a WDR7-7 inhibitor, confirming that the calycosin-induced inhibition of breast cancer cell proliferation involves the WDR7-7-GPR30 pathway. Additionally, the finding that calycosin inhibited both the miR-375-ERα feedback loop and the WDR7-7-GPR30 pathway in ER+ breast cancer cells may explain why ER+ breast cancer cells seem to be more sensitive to calycosin than ER− breast cancer cells. In ER− MCF10A cells, calycosin failed to trigger both pathways and, therefore, exerted no effect on cell growth.
Some studies have determined that GPR30 can be stimulated by estrogen to activate numerous cell signaling pathways through the transactivation of the EGFR/ERK pathway [33–35]. For example, in ER− breast cancer cells, GPR30 activates the tyrosine kinase SRC through the Gβγ subunit, which stimulates the autophosphorylation of EGFR to initiate MAP-kinase ERK1/2 and phosphatidylinositol 3 kinase (PI3K) signaling, ultimately inducing proliferation [36, 37]. As expected, we found that after reducing GPR30 expression, calycosin caused a decrease the phosphorylation levels of SRC, EGFR, ERK1/2, and Akt in breast cancer cell lines with and without ER expression (MCF-7, T47D, MDA-MB-468, and SKBR3), but calycosin did not affect the expression of p-SRC, p-EGFR, p-ERK1/2, or p-Akt in GPR30-deficient MDA-MB-231 cells. Pretreatment with a WDR7-7 inhibitor attenuated these effects in all four cell lines, but pretreatment with the pCDNA3.1-WDR7-7 vector promoted the calycosin-induced inhibition of these protein activities. These results suggest that SRC, EGFR, ERK1/2, and Akt help mediate the proliferation of breast cancer cells as downstream mediators of the WDR7-7-GPR30 pathway.
Altogether, the present study provides in vitro and in vivo evidence for a better understanding of the novel mechanisms by which calycosin inhibits the proliferation of breast cancer cells, especially ER− breast cancer cells. These actions likely involve the WDR7-7-GPR30 pathway, which then inactivates the MAPK and PI3K/Akt pathways via down-regulation of SRC and EGFR (Fig. 5h). Therefore, WDR7-7 and GPR30 may be potential mediators of the anti-cancer activity of calycosin that function alongside traditional estrogen receptors and may serve as additional biological targets in estrogen-sensitive tumors.
This work was supported, in part, by grants from the National Natural Science Foundation of China (81660610, 81460403) and the Natural Science Foundation of Guangxi (2015GXNSFBB139006).
JT carried out the molecular genetic studies and drafted the manuscript. YW carried out the molecular genetic studies and participated in the sequence alignment. XZ and QR carried out the immunoassays. RL participated in the sequence alignment. YH participated in the design of the study and performed the statistical analysis. HL performed the statistical analysis. JC conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42.View ArticlePubMedGoogle Scholar
- Houghton LC, Ganmaa D, Rosenberg PS, Davaalkham D, Stanczyk FZ, Hoover RN, et al. Associations of breast cancer risk factors with premenopausal sex hormones in women with very low breast cancer risk. Int J Environ Res Public Health. 2016;13:1066.View ArticlePubMed CentralGoogle Scholar
- Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006;101:246–53.View ArticlePubMedGoogle Scholar
- Kucuk O. Soy foods, isoflavones, and breast cancer. Cancer. 2017;123:1901–3.View ArticlePubMedGoogle Scholar
- Uifălean A, Schneider S, Ionescu C, Lalk M, Iuga CA. Soy isoflavones and breast cancer cell lines: molecular mechanisms and future perspectives. Molecules. 2015;21:E13.View ArticlePubMedGoogle Scholar
- Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF, et al. Understanding genistein in cancer: the “good” and the “bad” effects: a review. Food Chem. 2016;196:589–600.View ArticlePubMedGoogle Scholar
- Bilal I, Chowdhury A, Davidson J, Whitehead S. Phytoestrogens and prevention of breast cancer: the contentious debate. World J Clin Oncol. 2014;5:705–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Andrade JE, Ju YH, Baker C, Doerge DR, Helferich WG. Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model. Mol Nutr Food Res. 2015;59:413–23.View ArticlePubMedGoogle Scholar
- Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006;66:1241–9.View ArticlePubMedGoogle Scholar
- Wang WZ, Liu HO, Wu YH, Hong Y, Yang JW, Liu YH, et al. Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1. J Exp Clin Cancer Res. 2010;29:140.View ArticlePubMedPubMed CentralGoogle Scholar
- Tian J, Duan YX, Bei CY, Chen J. Calycosin induces apoptosis by upregulation of RASD1 in human breast cancer cells MCF-7. Horm Metab Res. 2013;45:593–8.View ArticlePubMedGoogle Scholar
- Chen J, Hou R, Zhang X, Ye Y, Wang Y, Tian J. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One. 2014;9:e91245.View ArticlePubMedPubMed CentralGoogle Scholar
- Lavorgna G, Vago R, Sarmini M, Montorsi F, Salonia A, Bellone M. Long non-coding RNAs as novel therapeutic targets in cancer. Pharmacol Res. 2016;110:131–8.View ArticlePubMedGoogle Scholar
- Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a Pharmacogenomic basis for the response of breast cancer patients to Aromatase inhibitor therapy. Cancer Res. 2016;76:7012–23.View ArticlePubMedGoogle Scholar
- Latorre E, Carelli S, Raimondi I, D'Agostino V, Castiglioni I, Zucal C, et al. The ribonucleic complex HuR-MALAT1 represses CD133 expression and suppresses epithelial-Mesenchymal transition in breast cancer. Cancer Res. 2016;76:2626–36.View ArticlePubMedGoogle Scholar
- Wang C, Liu Y, Cao JM. G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids. Int J Mol Sci. 2014;15:15412–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Girgert R, Emons G, Grundker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat. 2012;134:199–205.View ArticlePubMedPubMed CentralGoogle Scholar
- Jiang Z, Guo J, Shen J, Jin M, Xie S, Wang L. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells. J Exp Clin Cancer Res. 2012;31:42.View ArticlePubMedPubMed CentralGoogle Scholar
- Weissenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, et al. GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol. 2014;140:713–23.View ArticlePubMedGoogle Scholar
- Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM, Chen XH, et al. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 2014;e1428:5.Google Scholar
- de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70:9175–84.View ArticlePubMedGoogle Scholar
- Scaling AL, Prossnitz ER, Hathaway HJ. GPER mediates estrogen-induced signaling and proliferations in human breast epithelial cells, and normal and malignant breast. Horm Cancer. 2014;5:146–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Lappano R, Pisano A, Maggiolini M. GPER function in breast cancer: an overview. Front Endocrinol (Lausanne). 2014;5:66.Google Scholar
- Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73:2025–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Capper CP, Rae JM, Auchus RJ. The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer. Horm Cancer. 2016;7:149–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Sirotkin AV, Harrath AH. Phytoestrogens and their effects. Eur J Pharmacol. 2014;741:230–6.View ArticlePubMedGoogle Scholar
- Roca P, Sastre-Serra J, Nadal-Serrano M, Pons DG, Blanquer-Rosselló Mdel M, Oliver J. Phytoestrogens and mitochondrial biogenesis in breast cancer. Influence of estrogen receptors ratio. Curr Pharm Des. 2014;20:5594–618.View ArticlePubMedGoogle Scholar
- Lappano R, Maggiolini M. Pharmacotherapeutic targeting of G protein-coupled receptors in oncology: examples of approved therapies and emerging concepts. Drugs. 2017;77:951–65.View ArticlePubMedGoogle Scholar
- Wang D, Hu L, Zhang G, Zhang L, Chen C. G protein-coupled receptor 30 in tumor development. Endocrine. 2010;38:29–37.View ArticlePubMedGoogle Scholar
- Pisano A, Santolla MF, De Francesco EM, De Marco P, Rigiracciolo DC, Perri MG, et al. GPER, IGF-IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancer-associated fibroblasts. Mol Carcinog. 2017;56:580–93.View ArticlePubMedGoogle Scholar
- Zhou K, Sun P, Zhang Y, You X, Li P, Wang T. Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. Steroids. 2016;111:113–20.View ArticlePubMedGoogle Scholar
- Yu T, Liu M, Luo H, Wu C, Tang X, Tang S, et al. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells. J Steroid Biochem Mol Biol. 2014;143:392–403.View ArticlePubMedGoogle Scholar
- Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr Cancer Drug Targets. 2012;12:531–42.View ArticlePubMedGoogle Scholar
- Sheng ZG, Zhu BZ. Low concentrations of bisphenol a induce mouse spermatogonial cell proliferation by G protein-coupled receptor 30 and estrogen receptor-α. Environ Health Perspect. 2011;119:1775–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, et al. Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development. Cancer Treat Rev. 2017;53:111–9.View ArticlePubMedGoogle Scholar
- Wróbel AM, Gregoraszczuk EŁ. Action of methyl-, propyl- and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells. Toxicol Lett. 2015;238:110–6.View ArticlePubMedGoogle Scholar